HomeABUS • NASDAQ
add
Arbutus Biopharma Corp
Previous close
$2.71
Day range
$2.70 - $2.82
Year range
$1.69 - $3.29
Market cap
528.41M USD
Avg Volume
1.62M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | 1.53M | -77.09% |
Operating expense | 20.72M | 273.11% |
Net income | -17.88M | -9.40% |
Net profit margin | -1.17K | -377.52% |
Earnings per share | -0.14 | -1.04% |
EBITDA | -18.83M | -12.06% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 129.24M | -11.92% |
Total assets | 150.29M | -21.41% |
Total liabilities | 35.65M | -24.64% |
Total equity | 114.64M | — |
Shares outstanding | 175.63M | — |
Price to book | 4.17 | — |
Return on assets | -32.55% | — |
Return on capital | -40.39% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | -17.88M | -9.40% |
Cash from operations | -19.30M | 29.32% |
Cash from investing | 11.69M | -29.88% |
Cash from financing | 24.43M | 19.66% |
Net change in cash | 16.82M | 71.63% |
Free cash flow | -14.89M | 18.01% |
About
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Founded
2007
Headquarters
Website
Employees
73
